覃文新 Wenxin Qin

上海市肿瘤研究所研究员。武汉大学生物系生物化学理学学士，苏州医学院医学硕士，上海医科大学医学科学博士。美国系统生物学研究所访问学者。美国肝病研究学会Hepatology Communications杂志副主编。先后主持国家863计划、国家973计划、国家科技重大专项、国家自然科学基金重点国际合作课题等。在Lancet Oncology、Nature、Nature Communications、Gastroenterology、Hepatology等学术期刊发表论文120余篇。代表工作有，发现分泌蛋白DKK1与甲胎蛋白联合，可提高肝细胞癌的诊断率（Lancet Oncology 2012）；揭示RCAN1.4是一个新型肝癌抑制分子，其下调可激活肝癌细胞CaN/NFAT信号通路，从而上调细胞因子IGF1和VEGFA的分泌，形成促癌微环境，促进肝癌恶性进展（Gastroenterology 2017）；探索利用肿瘤细胞突变特异诱导肝癌细胞衰老，再定向清除衰老癌细胞而不杀伤正常细胞的分步式肝癌精准治疗策略（Nature 2019）；发现仑伐替尼治疗无效的EGFR高表达肝癌患者，联合应用EGFR抑制剂治疗，可有效抑制肝癌进展（Nature 2021，封面论文）等。出版《肿瘤微环境》学术译著1部，参编《Primary Liver Cancer》英文著作1部。获美国专利2项、中国发明专利3项。研究方向：肿瘤分子机制、肿瘤微环境、肿瘤治疗。

Researcher at Shanghai Cancer Institute. Bachelor of Science in Biochemistry from Wuhan University Department of Biology, Master of Medicine from Soochow Medical College, Doctor of Medical Science from Shanghai Medical University. Visiting Scholar at the Institute for Systems Biology (USA). Associate Editor of Hepatology Communications journal of the American Association for the Study of Liver Diseases. Has successively led National 863 Program, National 973 Program, National Science and Technology Major Projects, and National Natural Science Foundation Key International Cooperation Projects. Has published over 120 papers in academic journals such as Lancet Oncology, Nature, Nature Communications, Gastroenterology, and Hepatology. Representative works include: discovery that secreted protein DKK1 combined with alpha-fetoprotein can improve the diagnosis rate of hepatocellular carcinoma (Lancet Oncology 2012); revealed that RCAN1.4 is a novel liver cancer suppressor molecule, and its downregulation can activate the CaN/NFAT signaling pathway in liver cancer cells, thereby upregulating the secretion of cytokines IGF1 and VEGFA, forming a pro-cancer microenvironment and promoting malignant progression of liver cancer (Gastroenterology 2017); explored the stepwise precision treatment strategy for liver cancer using tumor cell mutation-specific induction of liver cancer cell senescence, followed by targeted clearance of senescent cancer cells without harming normal cells (Nature 2019); discovered that for EGFR-high-expressing liver cancer patients who are ineffective to lenvatinib treatment, combined application of EGFR inhibitors can effectively inhibit liver cancer progression (Nature 2021, cover article). Published 1 academic translation “Tumor Microenvironment” and co-edited 1 English work “Primary Liver Cancer”. Obtained 2 US patents and 3 Chinese invention patents. Research directions: tumor molecular mechanisms, tumor microenvironment, tumor therapy.

1. Zhou Y, Wang S, Wu W, Ling J, Li H, Jia Q, Zheng J, Zheng X, Yu R, Wu Q, Shi Y, Lieftink C, Beijersbergen RL, Yuan S*, Bernards R*, Jin H*, Qin W*. Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer. EBioMedicine. 2023 Jan;87:104397.
2. Wang C*, Cao Y, Yang C, Bernards R*, Qin W*. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol. 2021 Oct;18(10):690-704.
3. Zuo Q, He J, Zhang S, Wang H, Jin G, Jin H, Cheng Z, Tao X, Yu C, Li B, Yang C, Wang S, Lv Y, Zhao F, Yao M, Cong W, Wang C, Qin W. PGC1α suppresses metastasis of HCC by inhibiting Warburg effect via PPARγ-dependent WNT/β-catenin/PDK1 axis. Hepatology. 2021 Feb;73(2):644-660.